^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    ArcherMET

    Company:
    Invitae Corp
    Type:
    Other Approval
    Related tests:
    Evidence Level:
    Sensitive: A1 - Approval

    [MET exon 14 mutation-Non Small Cell Lung Cancer-tepotinib]

    Source:
    EMD Serono
    Test:

    ArcherMET

    Title:
    TEPMETKO® (Tepotinib) Approved in Japan for Advanced NSCLC with METex14 Skipping Alterations
    Published date:
    03/25/2020
    Excerpt:
    ...Japanese Ministry of Health, Labour and Welfare (MHLW) has approved TEPMETKO®* (tepotinib) for the treatment of patients with unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations.
    Evidence Level:
    Sensitive: C4 – Case Studies

    [MET exon 14 mutation-Non Small Cell Lung Cancer-tepotinib]

    Source:
    Tokai J Exp Clin Med
    Test:

    ArcherMET

    Title:
    Tepotinib Improves Prognosis in an Elderly Patient with Poor Performance Status and MET Exon 14 Skipping Mutation-positive Non-small Cell Lung Cancer
    Published date:
    04/01/2022
    Excerpt:
    An 84-year-old man was diagnosed with non-small cell lung cancer (cT3N2M1c stage IVB)...the patient was found to be positive for the MET exon 14 skipping mutation with ArcherMET...treatment with tepotinib (500 mg/day) was started. After the start of tepotinib administration, his PS improved to 0-1 after 1 week, and the partial response was maintained for more than 12 months (Fig. 1E, F). No serious side effects other than mild lower leg edema were observed....This report shows that targeted treatment of the MET exon 14 skipping mutation may be beneficial, even for elderly patients with poor PS.